RUNX1 and acute lymphoblastic leukemia: Since over-treatment is one of the problems of the current treatment protocols, and ETV6-RUNX1 genetic subgroup is usually associated with a favorable prognosis, the treatments based on biomarkers are warranted, and our work may represent such a precision medicine opportunity in ALL.